About Us

GeneCentric’s mission is to become a leader in the development and commercialization of biomarkers and companion diagnostics that define cancer drug responders and drive success in drug development.

We apply our proprietary rT(I)ME Explorer Platform to identify RNA-based gene signatures in the form of molecular subtypes and drug response predictors that enable the development of precision cancer drugs while improving patient outcomes.

Our approach yields high-resolution gene signatures that are prognostic or predictive and applies them to immune-based, targeted and other cancer therapeutics. By commercializing our technology through strategic collaborations with diagnostics, pharmaceutical and biotechnology companies, we are continuously growing our pipeline of gene signatures and related diagnostics.


Michael V. Milburn, PhD

Chief Executive Officer and President


Kirk Beebe, PhD

Chief Scientific Officer

Chenyqua Shepard, CPA

Chief Operating Officer

Joel R. Eisner, PhD

Sr. Vice President - Clinical & Corporate Development

Myla Lai-Goldman, MD

Founder & Executive Chairperson

Arnold J. Levine, Phd


Michael V. Milburn, PhD

Chief Executive Officer and President

Charles M. Perou, PhD

Founder and Director

Clay B. Thorp

General Partner, Hatteras Venture Partners

N. Hayes

David Neil Hayes, MD MPH MS

Observer and Founder

Prasanth Reddy, MD, MPH, FACP


Don M. Hardison